DIAGNOSTIC TEST 730
Amphiphysin Antibodies (IgG)
Diagnostic test for antibodies against Amphiphysin. For suspicion of paraneoplastic syndrome and autoimmune encephalitis.
Accredited. View certificate [.pdf]
Indication
Suspicion of paraneoplastic syndrome and autoimmune encephalitis.
Sample material
Serum
- Minim. volume: 0,5 mL
- Minim. volume: 2,0 mL
Transport
Within Sweden
- room temperature
International
- cold
Method
Immunoblot/ Indirect immunofluorescence(IIF)
According to Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes, anti-neuronal antibodies should be detected by at least two independent methods to be reliable. At Wieslab IIF and immunoblot are used.
Reference interval
Serum
- Immunoblot: <5 negative
- Indirect Immunofluorescence: <1:10 negative
Likvor
- Immunoblot: negative
- Indirect immunofluorescence: negative
Result
Serum
- Immunoblot: results are reported as negative, borderline, or positive with an intensity value.
- Indirect immunofluorescence (IIF): results are reported as negative or positive. Positive results will be titrated.
CSF
- Immunoblot: results are reported as negative, borderline, or positive.
- Indirect immunofluorescence (IIF): results are reported as negative or positive.
Interpretation
Antibodies against Amphiphysin occur in patients with the paraneoplastic variant of Stiff person syndrome but can also be seen in limbic encephalitis and are associated with breast cancer and small cell lung cancer. Neurological symptoms can precede cancer diagnosis by up to 5 years.
Antibodies against Amphiphysin are graded as High-risk antibodies with a frequency of 80% of underlying cancer and a positive result yield 3 points PNS score, according to Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
References
- Lancaster E et al. Neurology. 2011. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. PMID: 21747075
- Zuliani L et al. J Neurol Neurosurg Psychiatry. 2012. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. PMID: 22448032
- Rosenfeld MR, Dalmau J. Neurol Clin. 2018. Paraneoplastic Neurologic Syndromes. PMID: 30072076
- Balint B et al. Brain. 2018. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. PMID: 29053777 Graus F et al. Neurol Neuroimmunol Neuroinflamm. 2021. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. PMID: 34006622
- Scheper T et al, EUROLINE_WB allows reliable differentiation of autoantibodies against neural antigens in patients with paraneoplastic neurological syndrome, In: “From proteinomic to Molecular Epidemiology: Relevance of Autoantibodies”, 6th Dresden Symposium on Autoantibodies. 2002, Vol 3, 562-563
- Garza M, Piquet AL. Front Neurol. 2021. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia. PMID: 34489848
Included in these panels
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.5 mL serum (plain serum tubes without additives).
CSF: At least 2 mL CSF (polypropylene tubes).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18